-
公开(公告)号:US08853202B2
公开(公告)日:2014-10-07
申请号:US12778913
申请日:2010-05-12
申请人: Xi Chen , Dean R. Dragoli , Pingchen Fan , Mark M. Gleason , Juan C. Jaen , Lianfa Li , Jeffrey P. McMahon , Jay Powers , Yibin Zeng , Penglie Zhang , Junfa Fan
发明人: Xi Chen , Dean R. Dragoli , Pingchen Fan , Mark M. Gleason , Juan C. Jaen , Lianfa Li , Jeffrey P. McMahon , Jay Powers , Yibin Zeng , Penglie Zhang , Junfa Fan
IPC分类号: A61K31/497 , A61P35/00 , A61P9/10 , C07D401/14 , C07D417/14 , C07D403/14
CPC分类号: C07D401/14 , C07D403/14 , C07D417/14
摘要: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
摘要翻译: 提供具有式I化合物或其药学上可接受的盐,水合物或N-氧化物,并且可用于结合CXCR7,并且治疗至少部分依赖于CXCR7活性的疾病。 因此,本发明还提供含有一种或多种上述化合物与药学上可接受的赋形剂混合的组合物。
-
公开(公告)号:US08343975B2
公开(公告)日:2013-01-01
申请号:US12557428
申请日:2009-09-10
申请人: Penglie Zhang , Yibin Zeng
发明人: Penglie Zhang , Yibin Zeng
IPC分类号: A61K31/497 , C07D487/00
CPC分类号: C07D487/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 4-amino-3-imidazoyl-pyrazolo[3,4-d]pyrimidine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
-
公开(公告)号:US20110014121A1
公开(公告)日:2011-01-20
申请号:US12749434
申请日:2010-03-29
申请人: Xi Chen , Pingchen Fan , Mark M. Gleason , Juan C. Jaen , Lianfa Li , Jeffrey P. McMahon , Jay Powers , Yibin Zeng , Penglie Zhang
发明人: Xi Chen , Pingchen Fan , Mark M. Gleason , Juan C. Jaen , Lianfa Li , Jeffrey P. McMahon , Jay Powers , Yibin Zeng , Penglie Zhang
IPC分类号: A61K51/00 , C07D417/06 , C07D417/14 , C07D401/14 , C07D413/14 , A61K31/551 , A61K49/00 , A61P35/00 , A61P29/00 , A61P25/00 , A61P43/00 , C12N5/071
CPC分类号: C07D401/14 , C07D403/14 , C07D417/14
摘要: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
摘要翻译: 提供具有式I化合物或其药学上可接受的盐,水合物或N-氧化物,并且可用于结合CXCR7,并且治疗至少部分依赖于CXCR7活性的疾病。 因此,本发明还提供含有一种或多种上述化合物与药学上可接受的赋形剂混合的组合物。
-
公开(公告)号:US20080058341A1
公开(公告)日:2008-03-06
申请号:US11752201
申请日:2007-05-22
申请人: Penglie Zhang , Andrew Pennell , John Wright , Wei Chen , Manmohan Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark Gleason , Yibin Zeng , Kevin Greenman
发明人: Penglie Zhang , Andrew Pennell , John Wright , Wei Chen , Manmohan Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark Gleason , Yibin Zeng , Kevin Greenman
IPC分类号: A61K31/497 , A61P43/00 , C07D401/00 , C07D487/00
CPC分类号: A61K31/496 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D487/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常为芳基哌嗪衍生物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US07777035B2
公开(公告)日:2010-08-17
申请号:US11752201
申请日:2007-05-22
申请人: Penglie Zhang , Andrew M. K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
发明人: Penglie Zhang , Andrew M. K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
IPC分类号: C07D471/04
CPC分类号: A61K31/496 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D487/04
摘要: Methods are provided for the synthesis of 1-[4-(substituted phenyl)-piperazin-1-yl ] -2- [3-(1H-imidazol-2-yl)-pyrazolo [3,4-b]pyridin-1-yl]-ethanone compounds via construction of the imidazole portion onto the corresponding aldehyde or nitrile compounds.
摘要翻译: 提供了合成1- [4-(取代的苯基) - 哌嗪-1-基] -2- [3-(1H-咪唑-2-基) - 吡唑并[3,4-b]吡啶-1 - 基] - 乙酮化合物通过将咪唑部分构建到相应的醛或腈化合物上。
-
公开(公告)号:US20100069396A1
公开(公告)日:2010-03-18
申请号:US12557428
申请日:2009-09-10
申请人: Penglie Zhang , Yibin Zeng
发明人: Penglie Zhang , Yibin Zeng
IPC分类号: A61K31/496 , C07D487/04 , A61P25/28 , A61P25/16 , A61P11/06 , A61P19/02
CPC分类号: C07D487/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 4-amino-3-imidazoyl-pyrazolo[3,4-d]pyrimidine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 该化合物是4-氨基-3-咪唑基 - 吡唑并[3,4-d]嘧啶衍生物,可用于药物组合物,治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照 。
-
公开(公告)号:US20130338157A1
公开(公告)日:2013-12-19
申请号:US13774938
申请日:2013-02-22
申请人: Penglie Zhang , Andrew M.K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
发明人: Penglie Zhang , Andrew M.K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
IPC分类号: C07D471/04 , C07D487/04
CPC分类号: A61K31/496 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D487/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
-
公开(公告)号:US08288373B2
公开(公告)日:2012-10-16
申请号:US12612638
申请日:2009-11-04
申请人: Xi Chen , Pingchen Fan , Mark M. Gleason , Juan C. Jaen , Lianfa Li , Jeffrey P. McMahon , Jay Powers , Yibin Zeng , Penglie Zhang
发明人: Xi Chen , Pingchen Fan , Mark M. Gleason , Juan C. Jaen , Lianfa Li , Jeffrey P. McMahon , Jay Powers , Yibin Zeng , Penglie Zhang
IPC分类号: A61K31/497 , C07D403/00
CPC分类号: C07D417/14 , C07D401/14
摘要: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
摘要翻译: 提供具有式I化合物或其药学上可接受的盐,水合物或N-氧化物,并且可用于结合CXCR7,并且治疗至少部分依赖于CXCR7活性的疾病。 因此,本发明还提供含有一种或多种上述化合物与药学上可接受的赋形剂混合的组合物。
-
公开(公告)号:US20110098308A1
公开(公告)日:2011-04-28
申请号:US12829312
申请日:2010-07-01
申请人: Penglie Zhang , Andrew M.K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
发明人: Penglie Zhang , Andrew M.K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
IPC分类号: A61K31/497 , C07D471/04 , A61P19/02 , A61P25/00 , A61P17/00 , A61P1/00 , A61P37/08 , A61P25/16 , A61P25/28
CPC分类号: A61K31/496 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D487/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常为芳基哌嗪衍生物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US20100150831A1
公开(公告)日:2010-06-17
申请号:US12612638
申请日:2009-11-04
申请人: Xi Chen , Pingchen Fan , Mark M. Gleason , Juan C. Jaen , Lianfa Li , Jeffrey P. McMahon , Jay Powers , Yibin Zeng , Penglie Zhang
发明人: Xi Chen , Pingchen Fan , Mark M. Gleason , Juan C. Jaen , Lianfa Li , Jeffrey P. McMahon , Jay Powers , Yibin Zeng , Penglie Zhang
IPC分类号: A61K51/04 , C07D243/08 , A61K31/551 , C07D403/14 , A61P35/00
CPC分类号: C07D417/14 , C07D401/14
摘要: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
-
-
-
-
-
-
-
-
-